Clinical Trials
2 trialsNCT05551507 2026-05-04
IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT06710288 2025-10-20
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
ImmunityBio, Inc.
Phase 2 Recruiting